Kuros Biosciences AG Stock Swiss Exchange
Equities
CH0325814116
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.675 CHF | +178.13% | +0.42% | +3.91% |
Apr. 24 | Kuros Biosciences Posts Higher Q1 Product Sales | MT |
Apr. 17 | Kuros Biosciences AG Approves Board of Director and Committee Changes | CI |
Sales 2022 | 17.99M 19.87M | Sales 2023 | 33.56M 37.08M | Capitalization | 128M 142M |
---|---|---|---|---|---|
Net income 2022 | -14M -15.47M | Net income 2023 | -13M -14.36M | EV / Sales 2022 | 1.76 x |
Net cash position 2022 | 22.08M 24.4M | Net cash position 2023 | 12M 13.25M | EV / Sales 2023 | 3.46 x |
P/E ratio 2022 |
-3.41
x | P/E ratio 2023 |
-9.18
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.71% |
Managers | Title | Age | Since |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 23-02-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott P. Bruder
BRD | Director/Board Member | 62 | 18-06-13 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
1st Jan change | Capi. | |
---|---|---|
-1.10% | 103B | |
+8.46% | 101B | |
+4.40% | 23.07B | |
-12.26% | 22.23B | |
-4.36% | 18.05B | |
-39.98% | 17.18B | |
-10.23% | 16.94B | |
+7.05% | 14.07B | |
+38.65% | 12.35B |